Extract
Sudden cardiac death presumably due to cardiac arrhythmias is one of the hypotheses to explain the observed higher cardiovascular mortality in the adaptive servo-ventilation (ASV) group of the SERVE-HF study [1, 2]. In this regard, we congratulate Tamisieret al. [3] for their efforts to clarify the effect of ASV on muscle sympathetic nerve activity (MSNA) in patients with central sleep apnoea (CSA) and heart failure with reduced left ventricular ejection fraction (HFrEF). Analysing data from an SERVE-HF ancillary study, they concluded that: 1) suppression of CSA with ASV did not seem to have a significant effect on chronic HFrEF-related sympathetic activation; and 2) simultaneous suppression of CSA and reduction in MSNA was associated with increased cardiovascular mortality. In our opinion, these conclusions might be different if some confounding factors were considered.
Abstract
Stratified analyses of ongoing trials will need to take adaptive servo-ventilation (ASV) efficacy into account before concluding on ASV impact on outcome measureshttps://bit.ly/3GpHAD4
Footnotes
利益冲突:a .布di无关sclose. D. Jaffuel reports personal fees for lectures and meeting attendance from Philips Healthcare and Lowenstein, personal fees for meeting attendance from Resmed, personal fees for lectures and meeting attendance, and non-financial support for board membership from SEFAM, grants and personal fees for lectures from Novartis, personal fees for lectures from Jazz, personal fees for advisory board work from Bioproject, personal fees for lectures and non-financial support for board membership from NOMICS, outside the submitted work. F. Roubille reports grants and personal fees from Novartis, personal fees from AstraZeneca, Servier, Boehringer, Vifor, Bayer, Pfizer, Novonordisk, Air Liquide, Abott and Lilly, outside the submitted work. J.P. Mallet has nothing to disclose.
- ReceivedJanuary 2, 2023.
- AcceptedJanuary 5, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contactpermissions{at}ersnet.org